Parstatin(mouse) TFA|西域试剂

Parstatin(mouse) TFA,99.71%

产品编号：Bellancom-P1261A| 分子式：C₁₉₁H₃₂₇F₃N₅₈O₅₉S₃| 分子量：4533.18

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1261A	￥1200.00	杭州北京（现货）
Bellancom-P1261A	￥3800.00	杭州北京（现货）
Bellancom-P1261A	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Parstatin(mouse) TFA

产品介绍

Parstatin(mouse) TFA 是具有细胞通透性的 PAR-1 凝血酶受体的肽类激动剂，是一种有效的血管生成抑制剂。

生物活性

Parstatin(mouse) TFA, a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.

体外研究

Parstatin (0-10 µM) increases recovery of LVDP in a concentration-dependent manner. The optimal concentration was 1 µM which produced a 23% recovery of LVDP.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Parstatin (single dose, 1-25 µg/kg, iv) administered prior to ischaemia confers immediate cardioprotection by recruiting the Gi-protein activation pathway including p38 MAPK, ERK1/2, NOS, and KATP channels. Parstatin exerts effects on both the cardiomyocytes and the coronary circulation to induce cardioprotection. This suggests a potential therapeutic role of parstatin in the treatment of cardiac injury resulting from ischaemia and reperfusion.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats at 8 weeks of age (250-300 g).
Dosage:	1-25 µg/kg.
Administration:	IV injected 15 min prior to ischaemia.
Result:	A significant decrease in infarct size was detected with the 5-15 µg/kg doses with 10 µg/kg as the optimal dose. These hearts had an infarct size of 46 ± 3% of the area at risk, which is a 26% reduction in infarct size compared with the control.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats at 8 weeks of age (250-300 g).
Dosage:	1-25 µg/kg.
Administration:	IV injected 15 min prior to ischaemia.
Result:	A significant decrease in infarct size was detected with the 5-15 µg/kg doses with 10 µg/kg as the optimal dose. These hearts had an infarct size of 46 ± 3% of the area at risk, which is a 26% reduction in infarct size compared with the control.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (22.06 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.2206 mL	1.1030 mL	2.2060 mL
5 mM	0.0441 mL	0.2206 mL	0.4412 mL
10 mM	0.0221 mL	0.1103 mL	0.2206 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture and light, under nitrogen